Literature DB >> 27183455

A contemporary cross-sectional study on dyslipidemia management, cardiovascular risk status, and patients' quality of life in Greece: The CHALLENGE study.

Dimitrios Alexopoulos1, Maria Anastasiou-Nana2, Moses S Elisaf3, Evangelos Liberopoulos3, Loukianos S Rallidis2, Constantinos H Davos4, Alexandros Moulis5, Nikos Nikas5, Evangelos Zacharis6, Panos Vardas6.   

Abstract

BACKGROUND: Prior studies conducted in Greece consistently indicate that dyslipidemia is suboptimally managed, while the burden of cardiovascular disease (CVD) and related risk factors is rising.
METHODS: CHALLENGE was a multicenter, cross-sectional study carried out following the publication of guidelines advocating stricter low-density lipoprotein cholesterol (LDL-C) targets. It primarily aimed to depict LDL-C target attainment, and to assess the cardiovascular risk status and quality of life (QoL) of patients treated in a primary or secondary CVD prevention setting who had received any medical intervention for cardiovascular risk modification within 6months of enrollment.
RESULTS: Between December 2012 and April 2013, 500 patients (55% males) aged (mean±SD) 62.0±11.7years, participated in the study. Cardiovascular risk according to the 2011 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines was 'very high', 'high', and 'moderate' in 61.2%, 23.4%, and 15.4%, respectively. Overall, 92.0% of patients were on lipid-lowering treatment, yet only 23.3% had attained their ESC/EAS-defined LDL-C target. LDL-C target attainment was more likely among 'moderate' versus 'very high' cardiovascular risk patients (odds ratio: 4.04; 95% confidence interval: 2.32-7.06; p<0.001). QoL improved as cardiovascular risk decreased (EQ-VAS 71.8±16.2 in the 'very high' versus 78.3±15.1 and 80.3±15.7 in the 'high' and 'moderate' risk groups; p<0.001). Time constraints and difficulties in implementation in daily practice were the investigator's main barriers for guideline utilization.
CONCLUSIONS: During contemporary management of dyslipidemia in Greece, LDL-C target attainment is suboptimal. There is an undoubted need for improvement and implementation of cardiovascular risk assessment in routine clinical practice.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CV risk; Dyslipidemia guideline adherence; ESC/EAS guidelines; LDL-C target; Quality of life

Mesh:

Substances:

Year:  2016        PMID: 27183455     DOI: 10.1016/j.ijcard.2016.05.003

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Reference values assessment in a Mediterranean population for small dense low-density lipoprotein concentration isolated by an optimized precipitation method.

Authors:  Bárbara Fernández-Cidón; Ariadna Padró-Miquel; Pedro Alía-Ramos; María José Castro-Castro; Marta Fanlo-Maresma; Dolors Dot-Bach; José Valero-Politi; Xavier Pintó-Sala; Beatriz Candás-Estébanez
Journal:  Vasc Health Risk Manag       Date:  2017-06-06

2.  Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II.

Authors:  Evangelos Liberopoulos; Loukianos Rallidis; Filio Spanoudi; Elena Xixi; Anselm Gitt; Martin Horack; Veronica Ashton; Philippe Brudi; Dominik Lautsch; Baishali Ambegaonkar; Moses Elisaf
Journal:  Arch Med Sci       Date:  2018-03-12       Impact factor: 3.318

3.  Assessing forgetfulness and polypharmacy and their impact on health-related quality of life among patients with hypertension and dyslipidemia in Greece during the COVID-19 pandemic.

Authors:  Kyriakos Souliotis; Theodoros V Giannouchos; Chistina Golna; Evangelos Liberopoulos
Journal:  Qual Life Res       Date:  2021-06-22       Impact factor: 3.440

4.  Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review.

Authors:  Eric Bruckert; Klaus Georg Parhofer; Jose Ramon Gonzalez-Juanatey; Børge Nordestgaard; Marcello Arca; Periklis Giovas; Kausik Ray
Journal:  Adv Ther       Date:  2020-03-21       Impact factor: 3.845

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.